Rinne J O, Iivanainen M, Metsähonkala L, Vainionpää L, Pääkkönen L, Någren K, Helenius H
Turku PET Centre, University of Turku, Finland.
J Neural Transm (Vienna). 2004 Jan;111(1):59-67. doi: 10.1007/s00702-003-0053-3.
We investigated the integrity of striatal dopaminergic system in seven patients with dopa-responsive dystonia (DRD). Dopamine transporter function ([(11)C]CFT) and D1 ([(11)C]NNC 756) and D2 receptors ([(11)C]raclopride) were studied in same patients using positron emission tomography. Compared to age-adjusted control values the dopamine D2 receptor availability was increased in DRD. The mean age-adjusted [(11)C]raclopride uptake was 116% of the control mean in the putamen (p = 0.004) and 114% in the caudate nucleus (p = 0.007). The mean [(11)C]NNC 756 uptake was not different between DRD patients and controls, the age-adjusted uptake in DRD being 93% of mean control value in the putamen (p = 0.20) and 95% in the caudate nucleus (p = 0.40). The dopamine transporter binding was not altered. The [(11)C]CFT uptake in DRD was 96% of the control value in the putamen (p = 0.64), and 95% in the caudate nucleus (p = 0.44). In conclusion, striatal dopamine D2 receptors availability is increased in DRD whereas dopamine D1 receptors and dopamine transporter ligand binding is unchanged. The pattern of changes in striatal dopaminergic system in DRD is different from that reported in juvenile Parkinson's disease. The increased D2 receptor availability may be due to reduced competition by endogenous dopamine or a compensatory response to dopamine deficiency, or both.
我们研究了7例多巴反应性肌张力障碍（DRD）患者纹状体多巴胺能系统的完整性。使用正电子发射断层扫描技术，对同一批患者的多巴胺转运体功能（[(11)C]CFT）、D1受体（[(11)C]NNC 756）和D2受体（[(11)C]雷氯必利）进行了研究。与年龄校正后的对照值相比，DRD患者的多巴胺D2受体可用性增加。壳核中年龄校正后的[(11)C]雷氯必利摄取量为对照平均值的116%（p = 0.004），尾状核中为114%（p = 0.007）。DRD患者与对照组之间的[(11)C]NNC 756摄取量无差异，DRD患者年龄校正后的摄取量在壳核中为对照平均值的93%（p = 0.20），在尾状核中为95%（p = 0.40）。多巴胺转运体结合未改变。DRD患者在壳核中的[(11)C]CFT摄取量为对照值的96%（p = 0.64），在尾状核中为95%（p = 0.44）。总之，DRD患者纹状体多巴胺D2受体可用性增加，而多巴胺D1受体和多巴胺转运体配体结合未改变。DRD患者纹状体多巴胺能系统变化模式与青少年帕金森病报道的不同。D2受体可用性增加可能是由于内源性多巴胺竞争减少或对多巴胺缺乏进行代偿反应，或两者兼而有之。
